Navigation Links
Lilly CEO Says Industry, Public Policy Must Pave Way For Innovation
Date:2/10/2011

LONDON, Feb. 10, 2011 /PRNewswire/ -- A new approach to research, along with public policies that support medical innovation, will help biopharmaceutical companies address stubborn diseases with potentially devastating personal and financial consequences, such as cancer and Alzheimer's disease, according to John Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company (NYSE: LLY).

Lechleiter made his remarks Thursday in London during a keynote address at The Economist's 2011 Pharma Summit: Reinventing Pharma for a New Generation. During his talk, Lechleiter said two imperatives are needed to secure the future of the research-based pharmaceutical industry: changing the way companies conduct research, and public policies that promote an environment in which medical innovation can flourish.

The burden of several diseases is soaring in many countries, including the U.K.

According to the Alzheimer's Research Trust, for instance, more than 800,000 people in the U.K. are directly affected by dementia at a cost of 23 billion pounds Sterling per year.

And yet, just when the world desperately needs more new medicines for diseases like Alzheimer's, "our industry is taking too long, we're spending too much, and we're producing far too little," Lechleiter told the audience.

Lechleiter said the case for biopharmaceutical research and new medications is compelling. Specifically, he noted that:

  • Innovative medicines have proven themselves time and again to be the most effective way to reduce costs and improve quality in health care.
  • Treatments for diseases that remain unconquered, like cancer and Alzheimer's, most likely will come from laboratories of biopharmaceutical companies.
  • Even diseases that are being treated today, like diabetes, require better solutions.

"Ironically, the crisis in our innovation model comes at a time when we have vastly more scientific knowledge and data than ever before," Lechleiter said. "But unless we change the way we do research, we won't translate this knowledge into advances for patients. In the face of diminishing results, we can't simply perform the same old rituals and hope for a different outcome."

Specifically, Lechleiter stressed the need for research-based pharmaceutical companies to be more networked, global, and entrepreneurial to bring innovative medicines to patients faster and at lower costs. Such a global network is enabling Lilly to strengthen its own R&D capabilities, while attracting molecules, funding, and expertise from partners – creating shared investment, risk, and reward, along with greater efficiencies.

Lechleiter said the new approach to research will be successful only if matched with regulations that support an environment of innovation.

"Even as we rebuild our R&D engine, we must build an environment where pharmaceutical innovation can thrive," he said. "As pressures on health care systems around the world continue to grow, we will continue to make the case that innovation is imperative, and to advocate for reforms that promote innovation rather than penalize it."

Currently, government leaders in the U.K. are debating health care reform options to ease the stress on tightening budgets. Lechleiter said the new approach to research will be successful only if matched with regulations that support an environment of innovation.

Biopharmaceutical research, Lechleiter said, has also preserved jobs in the U.K. and other developed countries. In the U.K., there are 72,000 direct jobs in the biopharmaceutical sector and 200,000 indirect jobs. At 12 million pounds each day, the biopharmaceutical industry invests more in R&D than any other sector in the U.K.

Equally important have been the medical advances: in the U.K. alone, average life expectancy increased by 30 years from 1901 to 1999.

"Indeed, encouraging medical innovation needs to be a key purpose of health care reforms in both the United States and the United Kingdom," Lechleiter said. "We must continually make the case for innovation through our words, but more importantly, through our actions and the value we bring to patients through innovative medicines."  

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. C-LLY    

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly and the Juvenile Diabetes Research Foundation Partner to Fund Regenerative Medicine Research in Type 1 Diabetes
2. Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
3. Lilly Reports Fourth-Quarter and Full-Year 2010 Results, Provides 2011 Financial Guidance
4. Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA
5. Cognizant Selected by Lilly to Deliver Commercial Operations Solutions to Enhance Sales and Marketing Effectiveness, Business Performance
6. Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2010 Financial Results Announcement
7. Statement From Lilly on FDA Advisory Committee Recommendation Regarding Liprotamase New Drug Application for Treatment of Exocrine Pancreatic Insufficiency
8. Lilly Announces Completion of Avid Acquisition and FDA Priority Review for florbetapir
9. Manchester College Receives $35 Million Grant From Lilly Endowment for School of Pharmacy
10. Lilly Statement Regarding President Obamas Meeting With U.S. Business Leaders
11. Lilly Suspends Phase III Trial in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... -- Global Health Intelligence (GHI), the leading healthcare ... published its 2017 ranking of the Best-Equipped Hospitals in ... analysis from GHI,s hospitals database for Latin America , ... The GHI database covers 86% of the hospitals in ... points for each institution in key areas such as beds, ...
(Date:5/9/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... it has earned a spot on Forbes, ... was ranked among 500 U.S. employers as well as ... and Services. The annual Forbes ... survey of over 30,000 employees across 25 industries. The ...
(Date:5/8/2017)... NEW YORK , May 8, 2017 ... in the transition from fee for service reimbursement. Black ... April 2017. 1.       The Market for ... 77% of physician practices with 3 or ... Compliance Technology Solutions by Q4. "Given the magnitude of ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... MA (PRWEB) , ... May 26, 2017 , ... On ... Act (AHCA), which narrowly passed the U.S. House on May 4, would result in ... be expected under continued implementation of the 2010 Patient Protection and Affordable Care Act ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled ... a new, informational blog post on insurance options. If a Bay Area patient has ... help save time and money. Visiting an in-network provider for a second opinion can ...
(Date:5/26/2017)... ... 2017 , ... “Cactus Jack: Against All Odds”: the story of Coach Cactus ... Against All Odds” is the creation of published author, Walter Hubbard, a retired wildlife ... Carlisle’s third child Jane. Walter. Walter and Jane have three adult children and ...
(Date:5/24/2017)... , ... May 24, 2017 , ... Altec ... participation in nVerge 2017 – a one-day technology conference in San Diego, CA. ... solution, which allows users to fully utilize and enhance their Sage ERP solutions by ...
Breaking Medicine News(10 mins):